ZFP36L1 and small cell lung carcinoma: While ZFP36L1 is typically expressed at low levels in the SCLC-A subtype, it is more highly expressed in the inflammatory subtype, suggesting that restoring ZFP36L1 expression could enhance the plasticity of the inflammatory subtype and inhibit NE differentiation and cell proliferation, offering a promising therapeutic avenue (94).